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ABSTRACT
Systemic sclerosis (SSc) is a complex disease which consists of autoimmunity, fibrosis and
vasculopathy. Most organ involvement in SSc patients is related to progressive fibrosis. Once
fibrosis progresses, it becomes impossible to maintain a normal structure histologically.
Therefore, treatment in cases with advanced fibrosis is quite difficult. On the other hand, the
role of vasculopathy is clear in the pathogenesis of SSc. Lethal organ disorders of SSc, such
as pulmonary arterial hypertension and scleroderma renal crisis, include severe signs of
advanced vasculopathy. Nailfold videocapillaroscopy (NVC) is a safe and crucial method for
evaluating microvasculopathy. The morphological changes and their progressions can be
detected and scored by NVC. Indeed, the microvascular damage and dysfunction represent
early markers of systemic sclerosis. Systemic sclerosis has clinical heterogeneity and the use
of NVC has been validated to help with early diagnosis and even treatment. Finally, NVC
may be useful in evaluating the pathogenesis of systemic sclerosis and its progression in
connection with other early biomarkers and functional tools.
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1. Introduction
In the treatment of rheumatoid arthritis (RA), the
rise of molecular targeted therapy, including biolog-
ics, has dramatically improved the prognosis [1]. In
contrast, there is very little evidence in the treatment
for skin sclerosis, which is the main symptom of sys-
temic sclerosis (SSc). Therefore, SSc is one of the
most refractory of autoimmune diseases. This is seen
in the cause of death in each disease. For example,
the main causes of death in patients with RA are
infectious diseases and malignancy, which are the
same as important causes of death in the general
population. However, more than half of the patients
diagnosed with SSc die as a direct consequence of it
[2]. In terms of the pathology, RA is composed of
bone metabolic abnormality and accompanying
autoimmunity and inflammation. Meanwhile, SSc is
a complex disease in which autoimmunity, fibrosis
and vasculopathy lead to a complex pattern of
organ-based complications with high mortality and
morbidity [3]. This complicated pathology has made
the development of treatment difficult.
It has been pointed out that composite tools are
needed to accurately assess autoimmunity, fibrosis
and vasculopathy [4]. However, it is difficult to
evaluate the disease activity in such a complex dis-
ease, and there are no validated methods accepted
globally. The establishment of a disease activity
score is ongoing [5].
Furthermore, regarding vasculopathy among the
three main pathologies of SSc, the evaluation of
microvascular damage using nailfold videocapillaro-
scopy (NVC) has been regarded as important [6]. In
2013, a collaboration of the American College of
Rheumatology and the European League Against
Rheumatism (ACR/EULAR) proposed a new set of
criteria for systemic sclerosis for the first time in
30 years [7,8]. Further items are given a weighted
score, and a score of more than 9 is diagnostic of
systemic sclerosis. These classification criteria
encompass a broader spectrum of systemic sclerosis,
including patients whose disease is in the early
stages, as well as those in the later stages, and have
excellent sensitivity and specificity. Of note, nailfold
capillary abnormalities were one of the new items in
these criteria. With this scoring system, it has
become possible to diagnose systemic sclerosis
before skin thickening of the fingers is detected.
In this article, we make a commentary on the
method and significance of NVC in SSc.
2. Pathogenesis of systemic sclerosis
As described above, SSc consists of autoimmunity,
fibrosis and vasculopathy. The presence of
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autoantibodies, which suggests the involvement of
autoimmunity, is one of the findings in systemic
sclerosis. In fact, antinuclear antibodies are detected
in the serum of most SSc patients, although the
mechanism by which antinuclear antibodies are pro-
duced has not been elucidated. SSc-related autoanti-
bodies are commonly used and have been well
investigated as prognostic factors in patients with
SSc [9]. Since clinical application of rituximab,
which is the B cell depletion therapy, has certain
effects [10–12], it has been suggested that auto-
immunity contributes to organ involvement. Thus,
autoimmunity could be considered as the treat-
ment target.
Most organ involvement in SSc patients is related
to fibrosis. Typical complications of SSc, such as
skin sclerosis and interstitial lung disease, are based
on the final fibrosis. As antifibrotic treatment, pirfe-
nidone and nintedanib (both are approved for idio-
pathic pulmonary fibrosis) are expected to be
applied as drugs for SSc, however, it is challenging
to target fibrosis. Once fibrosis progresses, it
becomes impossible to maintain a normal structure
histologically. Therefore, the treatment in cases with
progressive fibrosis is difficult.
Vasculopathy is the last factor. For instance, the
prevalence of Raynaud’s phenomenon is over 90%
in patients with SSc. Moreover, lethal organ disor-
ders of SSc, such as pulmonary arterial hypertension
and scleroderma renal crisis, have characteristics of
vasculopathy. Furthermore, vasculopathy not only
causes such organ involvement but also tissue hyp-
oxia associated with ischemia. It contributes to pro-
mote dysfunction and fibrosis in each organ.
Therefore, improvement of vasculopathy in SSc
patients is one of the key treatment targets. NVC is
established as a validated method to evaluate micro-
vascular damage and is considered to be indispens-
able in the diagnosis and treatment of SSc [13].
3. Evaluating microvascular damage by NVC
NVC represents the best and safest method to detect
and analyze morphological microvascular abnormal-
ities. Nailfold is the skin that overlaps the edge of a
fingernail. The dermis is thin at this site anatomic-
ally, and the capillary can be seen directly. Capillary
abnormalities of the nailfold are often seen in
patients with SSc. Since dermatoscopy (30 magnifi-
cations) suffices for distinguishing between normal
and abnormal nailfold capillaries, dermatoscopy has
been used to detect the nailfold capillaries in Japan.
Although dermatoscopy is convenient to carry out,
inexpensive and simple, it is not suitable for detailed
analysis of the capillary. On the other hand, NVC
can allow analyzing of the shape of a capillary in
detail at a high magnification of 200 or more and is
superior to dermatoscopy in that it can accurately
measure the length, thickness and twist, although
training for evaluation is required. From this point
of view, clinical research by NVC has been recog-
nized as useful for understanding the pathogenesis.
It is desirable that physicians caring for SSc patients
use videocapillaroscopy to take an accurate measure-
ment of the fineness and the number of capillaries.
Practically, NVC is performed using optical vid-
eocapillaroscopy equipped with a 200 magnification
probe and connected to image analysis software
such as Videocap (DS Medica, Italy), after the
immersion oil is applied to the nailfold. In order to
prevent vasospasm, the patient should be inside a
room with a temperature of 20–22 degrees for a
minimum of 15minutes before the NVC is exam-
ined. Nailfolds of the second, third, fourth and fifth
fingers are examined.
This way is a safe and non-invasive manner to
capture the nailfold capillaries. In a healthy subject
or in primary Raynaud’s phenomenon, there are
‘lots of thin and linear capillaries’ (Figure 1). This
describes the normal morphology of a capillary.
no enlarged capillaries
linear extension
× 200 
more than 9 capillaries per mm
(our case)
Figure 1. Representative photograph of healthy control.
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First, the normal vessel’s diameter is less than
20 lm. The diameter could exceed 20 lm in some
capillaries in healthy individuals. However, the
detection of even a single loop with a homogeneous
increase in diameter to more than 50 mm should be
considered a potential marker of microangiopathy.
Second, capillaries form a straight line toward the
distal. Finally, the number of capillaries is more
than nine within 1mm of the row of the nailfold
bed. In addition, abnormalities of these findings
(the fineness, direction and the number of capilla-
ries) are seen in patients with SSc. These sequential
capillaroscopic changes, which are the so-called
NVC scleroderma spectrum abnormality, are typical
of microvascular involvement in SSc.
4. Diagnosis of systemic sclerosis by NVC
The significance of NVC findings in the diagnosis
of SSc has been known for a long time [14]. In
2013, a collaboration of the American College of
Rheumatology and the European League Against
Rheumatism (ACR/EULAR) proposed a new set of
criteria for systemic sclerosis for the first time in
30 years [7,8]. One the most significant changes of
these criteria was that nailfold capillary abnormal-
ities were listed as one of the new items. The new
classification criteria for systemic sclerosis encom-
pass a broader spectrum of systemic sclerosis and
focus on early diagnosis [7,8]. Sensitivity and speci-
ficity were 91% and 92% for the new classification
criteria and 75% and 72% for the 1980 ACR classifi-
cation criteria. These criteria include ‘abnormal nail-
fold capillaries’. The definition of ‘abnormal nailfold
capillaries’ is enlarged capillaries and/or capillary
loss with or without pericapillary hemorrhages at
the nailfold. These findings will be described in
detail later.
5. Scoring of NVC scleroderma spectrum
abnormalities by NVC
In addition to the usefulness in diagnosis, pattern
classification of nailfold capillary changes in SSc has
a strong correlation with organ involvement [15].
One problem is that the way to evaluate the NVC
scleroderma spectrum abnormalities has not been
integrated yet. Standardization regarding the find-
ings of NVC has been proposed by the EULAR
study group on microcirculation in Rheumatic dis-
eases [16,17]. In general, qualitative interpretation of
capillaroscopy can be applied (see scleroderma pat-
terns by M Cutolo et al. below) and quantitative
interpretation is also being applied. In this way
standardly number of capillaries (density), measure-
ment of apical diameter (dimension), presence or
absence of hemorrhages and number of abnormal
shapes is being evaluated. This standard approach is
applicable to all rheumatic diseases [18].
Previous literature had described in SSc the fol-
lowing six capillaroscopic parameters [19]: (a)
irregularly enlarged capillary (Figure 2): an increase
in capillary diameter (homogeneous or irregu-
lar)> 20lm; (b) giant capillary (Figure 2): homoge-
neously enlarged loops with a diameter >50lm; (c)
micro hemorrhage (Figure 2): dark mass due to
hemosiderin deposit; (d) loss of capillaries
(Figure 3): reduction of the capillary number below
normal range (the normal range was adopted from
the literature: average of nine capillaries per linear
millimeter, counted at distal row of the nailfold); (e)
disorganization of the microvascular array (Figure
3): irregular capillary distribution and orientation,
together with shape heterogeneity of the loops and
(f) capillary abnormal shapes, i.e., ramifications
(Figure 3): branching, bushy or coiled capillaries,
often originating from a single normal sized capil-
lary. These parameters, excepting irregularly
irregularly enlarged capillarygiant capillary
× 200 
micro hemorrhage
(our case)
Figure 2. Representative photograph of irregularly enlarged capillary, giant capillary, and microhemorrhage.
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enlarged capillaries, characterize overt sys-
temic sclerosis.
With the combination of these findings, the NVC
can be categorized into three different qualitative
patterns: ‘early’, ‘active’ and ‘late’, which are clearly
distinct from the ‘normal’ pattern (Table 1). The
early pattern is characterized by few giant capillaries,
few capillary microhemorrhages and no evident loss
of capillaries (Figure 4). The active pattern com-
prises frequent giant capillaries, frequent capillary
microhemorrhages and moderate loss of capillaries
(Figure 5). The late pattern is characterized by
irregular enlargement of capillaries, almost absent
giant capillaries and microhemorrhages, severe loss
of capillaries with extensive avascular areas, ramified
capillaries and intense disorganization of the normal
capillary array (Figure 6). Natural progression of
microvascular damage starts from the early pattern
and proceeds to the late pattern [20]. These con-
cepts are similar to the Steinbrocker radiographic
stage score in RA (Figure 7). The presence of anti-
Scl70 antibodies seems to be related to the earlier
expression of the active and late patterns. On the
other hand, the anti-centromere antibody seems to
be related to the delayed expression of the late NVC
pattern [21].
loss of capillaries
capillary ramifications
× 200 
disorganization of the microvascular array
(our case)
Figure 3. Representative photograph of disorganization of loss of capillaries, microvascular array, and capillary ramifications.
Table 1. Definition of each pattern of NVC scleroderma spectrum abnormalities.
Early pattern Active pattern Late pattern
Giant capillaries <33% Giant capillaries >33%
Capillary microhemorrhage >33%
Giant capillaries <33%
Capillary microhemorrhage <33%
No loss of capillaries
No disorganization of the capillary array
No ramified capillaries
Loss of capillaries <66%
Disorganization of the capillary array <66%
Ramified capillaries <33%
Loss of capillaries >66%
Disorganization of the capillary array >66%
Ramified capillaries >66%
× 200 (our case)Early pattern
Figure 4. Representative photograph of ‘early pattern’.
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× 200 (our case)Active pattern
Figure 5. Representative photograph of ‘active pattern’.
× 200 (our case)Late pattern
Figure 6. Representative photograph of ‘late pattern’.
stage I stage II stage III stage IV
Early pattern Active pattern Late patternNormal
NVC scleroderma spectrum abnormality
Steinbrocker radiographic stage score
Figure 7. Comparison between NVC scleroderma spectrum abnormality and Steinbrocker radiographic stage score.
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6. Correlation between patterns of NVC
scleroderma spectrum abnormalities and
organ involvement
It is well known that the patterns of NVC sclero-
derma spectrum abnormalities are closely correlated
to organ involvement in patients with SSc [22].
Interstitial lung disease and pulmonary artery hyper-
tension [23] and skin ulcers [24] are common in
cases with NVC scleroderma spectrum abnormal-
ities. In particular, the loss of capillaries with exten-
sive avascular areas is an important finding, and
there are many reports that a late NVC pattern sug-
gests the presence of organ involvement. Among
them, the largest retrospective multicenter (110
facilities) collaborative study by EULAR scleroderma
trials and research (EUSTAR) database showed a
correlation between organ involvement and vascul-
opathy [25]. In this study, the researchers investi-
gated the correlation between the pattern of NVC
scleroderma spectrum abnormalities and clinical
findings. In 494 early pattern cases, 778 active pat-
tern cases and 598 late pattern cases, complications
of organ involvement, such as skin ulcer, pulmonary
artery hypertension, interstitial lung disease and
joint contractures increased with the progression of
NVC scleroderma spectrum abnormalities. This can
be thought of as indirect evidence that organ
involvement of SSc occurs, based on vasculopathy.
The prognostic value of NVC scleroderma spec-
trum abnormalities in predicting SSc disease pro-
gression has been also reported. For example, the
strength of the association between NVC sclero-
derma spectrum abnormalities and future digital
ulcer has been indicated [26]. It has been reported
that NVC abnormalities predict skin ulcers [27].
However, most of the other studies contain retro-
spective bias that cannot be ignored, and it is diffi-
cult to say whether NVC abnormality can predict
future organ involvement. One prospective study
has indicated the possibility of prognostic prediction
by NVC findings [28], and prospective trials in a
multicenter collaboration are desired in the future.
7. Conclusion
Here, we described the practical evaluation methods
of microvascular damage and the significance of
NVC scleroderma spectrum abnormality in patients
with SSc. For the development of disease-specific
treatment, it is necessary to overcome the hetero-
geneity of SSc patients. Multilateral, comprehensive
and accurate evaluation, including vasculopathy,
autoimmunity and fibrosis, can lead to elucidate the
pathogenesis of SSc.
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